GSK is planning five Phase 3 studies for an antibody-drug conjugate it licensed from Chinese partner Hansoh Pharma, targeting gynecological cancers. Early data shared Sunday was strong enough to convince the UK company to move at scale.
Running five simultaneous Phase 3 trials is a bet most companies don’t make on early results alone. ADC assets have become among oncology’s most competed-over, and GSK’s decision to go wide signals it believes the Hansoh drug can work across multiple tumor types or patient populations in gynecological cancer.
The Hansoh partnership puts GSK in line with Western pharma’s recent approach: licensing ADC candidates from Chinese companies to fill oncology pipeline gaps. If the Hansoh program succeeds, it validates that strategy and lifts the value of every ADC asset Hansoh hasn’t yet licensed. Other Western companies will be watching.
For gynecological cancer patients, five concurrent Phase 3s could mean faster answers than a sequential development approach would deliver.
Data was shared Sunday, April 12, 2026.
Sarah Chen